Table 4.
Association Between Current Opioid Misuse Measure Score With Receipt of Monitoring and With Satisfaction Toward the Monitoring in a Cohort of Human Immunodeficiency Virus–Infected Patients on Chronic Opioid Therapy for Chronic Pain
| Independent Variable | Outcome | No.a | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|---|
| COMM score ≥9 | Pain treatment agreementb | 156 | 2.02 (1.02–3.99) | 1.82 (.89–3.74) |
| Urine drug testb | 162 | 1.10 (.56–2.13) | 1.01 (.50–2.04) | |
| Pill countc | 165 | 1.73 (.68–4.44) | 1.59 (.60–4.26) | |
| Satisfaction with pain treatment agreemente | 50 | 0.38 (.11–1.24) | 0.36 (.10–1.25) | |
| Satisfaction with urine drug screend | 110 | 0.55 (.25–1.20) | 0.54 (.22–1.29) | |
| Satisfaction with pill counte | 20 | 0.67 (.11–3.92) | 0.52 (.05–5.05) |
Abbreviations: CI, confidence interval; COMM, Current Opioid Misuse Measure; OR, odds ratio.
aSample size varies because individuals who responded “I don’t know” were excluded. Sample size for satisfaction only includes those who responded affirmatively to receiving the respective monitoring practice.
bAdjusted for: age, gender, race, past year substance use disorder, ever had opioid overdose.
cAdjusted for: gender, substance use disorder in the past 12 months.
dAdjusted for: age, gender, race, substance use disorder in the past 12 months, ever had opioid overdose.
eAdjusted for: gender, substance use disorder in the past 12 months.